These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8917393)

  • 1. Nanoerythrosomes, a new derivative of erythrocyte ghost II: identification of the mechanism of action.
    Moorjani M; Lejeune A; Gicquaud C; Lacroix J; Poyet P; Gaudreault RC
    Anticancer Res; 1996; 16(5A):2831-6. PubMed ID: 8917393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoerythrosomes, a new derivative of erythrocyte ghost: III. Is phagocytosis involved in the mechanism of action?
    Lejeune A; Poyet P; Gaudreault RC; Gicquaud C
    Anticancer Res; 1997; 17(5A):3599-603. PubMed ID: 9413209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoerythrosome, a new derivative of erythrocyte ghost: preparation and antineoplastic potential as drug carrier for daunorubicin.
    Lejeune A; Moorjani M; Gicquaud C; Lacroix J; Poyet P; Gaudreault R
    Anticancer Res; 1994; 14(3A):915-9. PubMed ID: 8074493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoerythrosomes, a new derivative of erythrocyte ghost: IV. Fate of reinjected nanoerythrosomes.
    Désilets J; Lejeune A; Mercer J; Gicquaud C
    Anticancer Res; 2001; 21(3B):1741-7. PubMed ID: 11497254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythrocyte membrane-bound daunorubicin as a delivery system in anticancer treatment.
    Gaudreault RC; Bellemare B; Lacroix J
    Anticancer Res; 1989; 9(4):1201-5. PubMed ID: 2817803
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interaction of DNR and glutaraldehyde with cell membrane proteins leads to morphological changes in erythrocytes.
    Marczak A; Jóźwiak Z
    Cancer Lett; 2008 Feb; 260(1-2):118-26. PubMed ID: 18060688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folate receptor targeted delivery of liposomal daunorubicin into tumor cells.
    Ni S; Stephenson SM; Lee RJ
    Anticancer Res; 2002; 22(4):2131-5. PubMed ID: 12174894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in the toxicity and therapeutic efficacy of daunorubicin linked with a biodegradable carrier.
    Hrdina R; Bogusová TA; Kunová A; Kvĕtina J
    Neoplasma; 1991; 38(3):265-73. PubMed ID: 1857447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of erythrocyte-bound daunorubicin in patients with acute leukemia.
    Skorokhod OA; Garmaeva TTs; Vitvitsky VM; Isaev VG; Parovichnikova EN; Savchenko VG; Ataullakhanov FI
    Med Sci Monit; 2004 Apr; 10(4):PI55-64. PubMed ID: 15039656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytotoxicity of daunorubicin in trisomic (+21) human fibroblasts: relation to drug uptake and cell membrane fluidity.
    Przybylska M; Koceva-Chyla A; Rózga B; Józwiak Z
    Cell Biol Int; 2001; 25(2):157-70. PubMed ID: 11237420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ROS production and their influence on the cellular antioxidative system in human erythrocytes incubated with daunorubicin and glutaraldehyde.
    Marczak A; Bukowska B
    Environ Toxicol Pharmacol; 2013 Jul; 36(1):171-81. PubMed ID: 23612522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversible targeting and controlled release delivery of daunorubicin to cancer cells by aptamer-wrapped carbon nanotubes.
    Taghdisi SM; Lavaee P; Ramezani M; Abnous K
    Eur J Pharm Biopharm; 2011 Feb; 77(2):200-6. PubMed ID: 21168488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Altered subcellular distribution of daunorubicin in the non-P-glycoprotein-mediated multidrug-resistant cell line HL-60/ADR].
    Gong Y; Wang Y; Chen F; Han J; Shao N; Fang Z; Ouyang R
    Zhonghua Xue Ye Xue Za Zhi; 2000 Jun; 21(6):309-11, 2. PubMed ID: 11876999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daunorubicin-induced cell kill with 1-hour versus 24-hour infusions: a randomized comparison in children with newly diagnosed acute lymphoblastic leukemia.
    Escherich G; Göbel U; Jorch N; Spaar HJ; Janka-Schaub GE
    Klin Padiatr; 2007; 219(3):134-8. PubMed ID: 17525906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo.
    Versluis AJ; Rump ET; Rensen PC; van Berkel TJ; Bijsterbosch MK
    J Pharmacol Exp Ther; 1999 Apr; 289(1):1-7. PubMed ID: 10086980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Release of daunorubicin from polymethylmethacrylate for the improvement of the local growth control of bone metastasis animal experiments.
    Fröschle GW; Mählitz J; Langendorff HU; Achilles E; Pollock J; Jungbluth KH
    Anticancer Res; 1997; 17(2A):995-1002. PubMed ID: 9137440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drastic effect of cell density on the cytotoxicity of daunorubicin and cytosine arabinoside.
    Masquelier M; Vitols S
    Biochem Pharmacol; 2004 May; 67(9):1639-46. PubMed ID: 15081863
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [High-density lipoproteins as a form of daunorubicin transport in hepatoma cells of mice].
    Sumenkova DV; Poliakov LM; Panin LE
    Eksp Klin Farmakol; 2012; 75(5):32-4. PubMed ID: 22834127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomicelle formulation modifies the pharmacokinetic profiles and cardiac toxicity of daunorubicin.
    Zhang H; Li Y; Lin TY; Xiao K; Haddad AS; Henderson PT; Jonas BA; Chen M; Xiao W; Liu R; Lam KS; Pan CX
    Nanomedicine (Lond); 2014; 9(12):1807-20. PubMed ID: 24628688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular pharmacology and antitumor activity of N-(p-azidobenzoyl)-daunorubicin, a photoactive anthracycline analogue.
    Averbuch SD; Clawson RE; Bachur NR; Felsted RL
    Cancer Chemother Pharmacol; 1986; 16(3):211-7. PubMed ID: 2421935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.